%0 Journal Article
%T Clinical Evaluation of Some Biochemical Markers in Multiple Myeloma among Egyptian Patients
%A Magda Sayed
%A Mie Afify Mohammed
%A Ola Khorshid
%J Journal of Medical Sciences
%D 2007
%I 
%X The objective of the current study was to evaluate the circulating levels of mediators such as interleukin-6 (IL-6), ¦Â-2 microglobulin (¦Â2-M), lactate dehydrogenate (LDH), total alkaline phosphatase (TALP), bone alkaline phosphatase (BALP) and C-reactive protein (CRP) before and after treatment in patients with MM. Testing these biochemical markers might help in the identification, staging, determining its severity and monitoring the response to treatment of the myeloma patients. It was determined serum levels IL-6, ¦Â2-M, LDH, TALP, BALP and CRP in 28 newly diagnosed (group I) and 23 after treatment (group II) in patients with MM. The mean age of the patients was 59.63 and 61.55 years, respectively. All patients were in stage III (classified according to the Durie-Salmon classification). The same parameters were measured in 15 healthy controls with a mean age of 58.06 years. The results showed that the serum levels of IL-6 (pg mL1), beta-2 microglobulin (¦Ìg mL1), CRP (mg mL1) and LDH (U L1) were increased in-group (I) and this increment were highly significant (p< 0.001) on comparison with the control group and group (II). The serum level of TALP and BALP (U L1) were increased in-group (I) and this increment was slightly significant (p< 0.05) on comparison with the control group and group (II). All of the parameters were found to be significantly reduced after chemotherapy treatment. The serum level of T ALP in-group (II) decreased but did not reached the normal value and there was significant increased as compared to the control group (p< 0.05). There were a significant positive correlation (p< 0.05) between serum level of IL-6 and beta-2 microglobulin, CRP, LDH, TALP and BALP, the r-values were 0.7319, 0.6875, 0.7528, 0.8119 and 0.7072, respectively in-group (I). In conclusion, It was found that after the therapy, the levels of these parameters, which are thought to play an important role in the pathogenesis of MM, were significantly suppressed denoting their importance in the prognosis and monitoring the MM disease.
%K interleukin-6
%K biochemical markers
%K Multiple myeloma
%K 2-microglobulin
%K LDH
%U http://docsdrive.com/pdfs/ansinet/jms/2007/942-951.pdf